Gavreto (pralsetinib)
pCPA File Number:
22032
Negotiation Status:
Concluded without agreement
Indication(s):
Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), rearranged during transfection (RET) fusion-positive, in adult patients
Sponsor/Manufacturer:
Hoffmann-La Roche Ltd.
CDA-AMC Project Number:
PC0283-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: